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Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
To the Editor: Johnson et al. (June 23 issue)1 
report that their trial included 172 patients with 
advanced-stage Hodgkin’s lymphoma who switched 
from doxorubicin, bleomycin, vinblastine, and 
dacarbazine (ABVD) to bleomycin, etoposide, 
doxorubicin, cyclophosphamide, vincristine, pro-
carbazine, and prednisone (BEACOPP) because 
of positive results on interim positron-emission 
tomography (PET) with 18F-f luorodeoxyglucose 
(FDG). Among these patients, the 3-year progres-
sion-free survival rate was 67.5% and the overall 
survival rate was 87.8%. These patients had more 
therapy-related adverse events than did patients 
who had negative results on interim FDG-PET 
and continued to receive ABVD chemotherapy. 
Unfortunately, the benefit of early intensification 
with BEACOPP in patients who had positive re-
sults on interim FDG-PET cannot be assessed 
because, as in other recent nonrandomized stud-
ies of chemotherapy intensification, the trial de-
sign did not include a randomized comparison 
between continuation of standard ABVD chemo-
therapy and intensified BEACOPP chemotherapy 
and because of futile comparisons with histori-
cal cohorts in trials in which the methods and 
results were not homogeneous.2
Remarkably, the German Hodgkin Study Group 
HD15 trial3 showed that 191 patients who con-
tinued to have positive findings on FDG-PET 
after six to eight cycles of BEACOPP had a good 
4-year progression-free survival rate of 86.2% 
after they received additional treatment with radia-
tion therapy. Comparable results were observed 
in studies that included patients who had early-
stage or advanced-stage Hodgkin’s lymphoma 
and received ABVD.4,5 These findings show that 
radiation therapy can successfully eradicate per-
sistent FDG-avid lesions after first-line therapy 
and that early intensification of chemotherapy 
may not be warranted in these patients.
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The authors reply: Adams and Kwee point out 
that the patients with positive findings on an in-
terim PET–computed tomographic (PET-CT) scan 
in our trial were not randomly assigned to con-
tinue ABVD. Instead, all these patients switched 
to BEACOPP regimens. A proposal for this group 
to undergo randomization was strongly rejected 
by patient representatives and investigators dur-
ing the trial design on the grounds that histori-
cal series showed unacceptably low rates of pro-
gression-free survival ranging from 13 to 28%. 
By comparison, three separate prospective stud-
ies showed that escalation to BEACOPP resulted 
in progression-free survival rates of 65 to 70%.1,2 
Further supportive evidence was provided in the 
Intergroup European Organization for Research 
and Treatment of Cancer–Lymphoma Study 
 Association–Fondazione Italiana Linfomi H10 
(EORTC/FIL H10) trial3 in which patients with 
early-stage disease who continued to have posi-
tive findings on an interim PET scan underwent 
randomization. Although all the patients received 
consolidation radiotherapy, the rate of progres-
sion-free survival at 5 years was higher among 
patients who received BEACOPP than among 
patients who continued to receive ABVD (91% 
vs. 77%).
Radiotherapy instead of intensified chemo-
therapy might be appropriate for patients with 
early-stage disease, but in our trial most patients 
who had positive PET findings had disease that 
was too extensive for a limited radiotherapy field. 
The long-term toxicity of extended-field radio-
therapy is well documented4 and is a strong 
reason to use interim PET scanning as a means 
to tailor therapy to individual patient responses 
and thereby minimize exposure to radiotherapy.
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Caregivers and Families of Critically Ill Patients
To the Editor: The study by Cameron and col-
leagues (May 12 issue)1 takes an expanded view 
of outcomes after critical illness. The authors 
found that many caregivers have persistent depres-
sive symptoms, which reveal the reverberations 
of illness beyond the index patient. This article 
and others2 highlight the need to revise the view 
of the patient from a solitary figure to a person 
embedded in a social network. A personal net-
work method offers the means to do this. Also 
called egocentric networks, this approach identi-
fies the various persons around a focal person 
and elaborates the structure and characteristics 
of the relationships.3 The personal network meth-
od explicates how a patient is situated in a com-
plex “social connectome” that is made of strong 
and weak relationships, kin and non-kin, and 
persons with varied health habits. It shows the 
ripples in the network that occur from health 
shocks such as sudden critical illness, stroke, 
and myocardial infarction; conversely, network 
characteristics probably affect outcomes. We look 
forward to future studies that take a network ap-
proach to better understand outcomes and sug-
gest targets for sustainable network recovery.
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To the Editor: The attention to the Perspective 
article by Wittenberg and Prosser (May 12 is-
sue)1 and the study by Cameron et al., which 
emphasize that a patient’s health both affects 
and is affected by the well-being of family mem-
bers, is timely. Both articles concern high-income 
countries with well-developed health systems. 
We want to stress that challenges for caregivers 
are even greater in low-income settings.2 With 
the increasing prevalence of chronic noncom-
municable diseases, families carry heavy bur-
dens in countries in which health care systems 
are oriented toward acute care populations. Our 
research on households in Uganda that include 
a member with type 2 diabetes has shown the 
difficulties of providing care. Apart from the 
high treatment cost and loss of income, house-
hold members also experienced stress related 
to the chronic illness.3 Although Wittenberg 
and Prosser underscore the negative effects on 
caregivers’ health, having a household member 
with type 2 diabetes may also benefit the car-
diometabolic health of other members.3,4 We 
suggested that diabetes education for patients 
should be family-based and agree that health is 
a family affair, not least in low-income coun-
tries.
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